Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Robots take on brainstem bleeds: a new hope?

NCT ID NCT06459427

Disease control Sponsor: Yanbing Yu Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether robot-assisted surgery can improve survival and recovery for people with a brainstem hemorrhage (bleeding in a critical brain area). About 142 adults with moderate to severe bleeding will either get the robot-guided procedure plus standard care, or standard care alone. The goal is to see if the robotic approach helps more people survive and regain function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 142 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Participants must meet all of the following inclusion criteria: 1. Age ≥18 years at randomization； 2. Diagnosed with brainstem hemorrhage via imaging (CT, CTA, etc.)； 3. Hematoma volume ≥3 mL； 4. Glasgow Coma Scale (GCS) score of 3-12； 5. Available for surgery within 48 hours after onset； 6. Modified Rankin Scale (mRS) score ≤ 1 prior to this hemorrhage； 7. Informed consent obtained in accordance with national laws, regulations, and applicable ethics committee requirements. Patients will be excluded if they meet any of the following criteria: 1. Hematoma involving other regions such as the supratentorial compartment, basal ganglia, thalamus, midbrain, or ventricles. 2. Radiologically confirmed cerebral vascular abnormalities including ruptured aneurysms, arteriovenous malformations (AVMs), or Moyamoya disease; hemorrhagic transformation of ischemic infarcts; or recent (within 1 year) recurrence of intracerebral hemorrhage； 3. Any irreversible coagulation disorder or known coagulopathy; platelet count \<100,000/µL; INR \>1.4; or use of anticoagulant medication within 7 days before the current hemorrhage； 4. Current or probable pregnancy； 5. Patients with concurrent severe illness likely to influence outcome assessment； 6. Difficulty in follow-up or poor compliance due to any cause.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brain stem hemorrhage are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Brain stem hemorrhage Robotic surgical procedures Stereotactic techniques

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aerospace Center Hospital

    Beijing, Beijing Municipality, 100049, China

  • China-Japan Friendship Hospital

    Beijing, Beijing Municipality, 100029, China

  • Hebei Provincial People's Hospital

    Shijiazhuang, Hebei, 100190, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.